As­traZeneca, Fi­bro­Gen flag ap­peal­ing pooled safe­ty da­ta on roxa for key seg­ment of the CKD mar­ket

As­traZeneca rolled out its pooled haz­ard ra­tios on rox­adu­s­tat safe­ty to­day, which helps map out how they plan to take on the huge ane­mia mar­ket for chron­ic kid­ney dis­ease pa­tients who have re­lied on EPO for decades — pro­vid­ed the FDA comes through with an OK.

The ba­sic break­down has to ad­dress 2 dif­fer­ent reg­u­la­to­ry stan­dards, us­ing MACE for the FDA and MACE+ for Eu­ro­pean reg­u­la­tors, where guide­lines add con­ges­tive heart fail­ure and angi­na hos­pi­tal­iza­tions to the mix of car­dio threats. Re­searchers have al­ready out­lined ap­peal­ing ef­fi­ca­cy num­bers. But As­traZeneca’s part­ner — Fi­bro­Gen — spooked an­a­lysts and in­vestors back in May when they fudged the top-line state­ment in­di­cat­ing there could be re­al trou­ble in key mar­ket seg­ments. The part­ners, though, ap­pear to have skirt­ed the worst-case sce­nario un­der­scored by a re­cent short at­tack, ex­pect­ing that key haz­ard ra­tios could scut­tle the drug en­tire­ly.

There was a clear step up in risk as in­ves­ti­ga­tors as­sessed the drug against place­bo for non-dial­y­sis CKD pa­tients, against EPO in dial­y­sis pa­tients, and against a pop­u­la­tion of pa­tients new-to-dial­y­sis, called in­ci­dent dial­y­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER